An interventional study of NICOTINE TABLET-0mg and NICOTINE TABLET-0.5mg in Attention, sponsored by Philip Morris Products S.A.. Completed at 1 site in Sweden. Open to participants aged 19 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-05.
Sponsored by Philip Morris Products S.A. (part of Philip Morris International) · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aims to provide initial insights into the impact of orally delivered nicotine on attentional performance in adult occasional users of nicotine pouches. Nicotine will be administered via a dissolvable tablet for approximately 10 minutes. The main objective of this exploratory study is to characterize the effect of nicotine on attentional performance, using metrics derived from Continuous Performance Test (CPT).
Additionally, a second CPT assessment will be conducted two hours after the first administration to explore the potential sustained effects of nicotine on attention as an exploratory objective.
Philip Morris Products S.A. is the lead sponsor of 49 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The list of possible sequences are: NT-0mg; NT-0.5mg; NT-1.0mg; NT-1.5mg; NT-2.0mg
Other: NICOTINE TABLET-0mg · Other: NICOTINE TABLET-0.5mg · Other: NICOTINE TABLET-1.0mg · Other: NICOTINE TABLET-1.5mg · Other: NICOTINE TABLET-2.0mg
The list of possible sequences are: NT-0mg; NT-0.5mg; NT-1.0mg; NT-1.5mg; NT-2.0mg
Other: NICOTINE TABLET-0mg · Other: NICOTINE TABLET-0.5mg · Other: NICOTINE TABLET-1.0mg · Other: NICOTINE TABLET-1.5mg · Other: NICOTINE TABLET-2.0mg
The list of possible sequences are: NT-0mg; NT-0.5mg; NT-1.0mg; NT-1.5mg; NT-2.0mg
Other: NICOTINE TABLET-0mg · Other: NICOTINE TABLET-0.5mg · Other: NICOTINE TABLET-1.0mg · Other: NICOTINE TABLET-1.5mg · Other: NICOTINE TABLET-2.0mg
The list of possible sequences are: NT-0mg; NT-0.5mg; NT-1.0mg; NT-1.5mg; NT-2.0mg
Other: NICOTINE TABLET-0mg · Other: NICOTINE TABLET-0.5mg · Other: NICOTINE TABLET-1.0mg · Other: NICOTINE TABLET-1.5mg · Other: NICOTINE TABLET-2.0mg
The list of possible sequences are: NT-0mg; NT-0.5mg; NT-1.0mg; NT-1.5mg; NT-2.0mg
Other: NICOTINE TABLET-0mg · Other: NICOTINE TABLET-0.5mg · Other: NICOTINE TABLET-1.0mg · Other: NICOTINE TABLET-1.5mg · Other: NICOTINE TABLET-2.0mg
NICOTINE TABLET (nicotine content 0mg; Mint flavor)
NICOTINE TABLET (nicotine content 0.5mg; Mint flavor)
NICOTINE TABLET (nicotine content 1.0mg; Mint flavor)
NICOTINE TABLET (nicotine content 1.5mg; Mint flavor)
NICOTINE TABLET (nicotine content 2.0mg; Mint flavor)
Change in attentional performance after 15 minutes
To evaluate the effect of nicotine on attentional performance following a 10-minute use of five NICOTINE TABLET variants containing 0 mg, 0.5 mg, 1.0 mg, 1.5 mg, or 2.0 mg nicotine. Attentional performance will be assessed 15 minutes after the start of product use using the Conners Continuous Performance Test (CPT).
Time frame: 15 minutes after the start of product use
Change in attentional performance after 2 hours
To evaluate the effect of nicotine on attentional performance following a 10-minute use of five NICOTINE TABLET variants containing 0 mg, 0.5 mg, 1.0 mg, 1.5 mg, or 2.0 mg nicotine. Attentional performance will be assessed 2 hours after the start of product use using the Conners Continuous Performance Test (CPT).
Time frame: 2 hours after the start of product use
Change in self-reported craving for nicotine pouch use
Participants will rate their craving on a 100 mm unipolar scale (0 = no craving, 100 = strong craving) in response to the question: "How strong is your craving for using a nicotine pouch?" following a 10-minute use of five NICOTINE TABLET variants containing 0 mg, 0.5 mg, 1.0 mg, 1.5 mg, or 2.0 mg nicotine.
Time frame: 10 minutes after the start of product use
Ran from Oct 2025 to primary completion in Mar 2026, 4 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.